These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8775764)

  • 1. Natural killer cell activity in major depression: a prospective study of the in vivo effects of desmethylimipramine treatment.
    Pariante CM; Miller AH
    Eur Neuropsychopharmacol; 1995; 5 Suppl():83-8. PubMed ID: 8775764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic effects of desmethylimipramine treatment on platelet serotonin uptake in depressed patients: a comparison with imipramine.
    Rausch JL; Moeller FG
    Psychiatry Res; 1991 Mar; 36(3):299-305. PubMed ID: 2062971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imipramine blood levels and clinical outcome.
    Rigal JG; Albin HC; Duchier AR; D'Aulnay JM; Fenelon JH; Vincon GA; Demotes-Mainard FM
    J Clin Psychopharmacol; 1987 Aug; 7(4):222-9. PubMed ID: 3624505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An inverse correlation between serum levels of desmethylimipramine and melatonin-like immunoreactivity in DMI-responsive depressives.
    Halbreich U; Weinberg U; Stewart J; Klein DF; Weitzman ED; Quitkin FM
    Psychiatry Res; 1981 Feb; 4(1):109-13. PubMed ID: 6938997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Hydroxydesipramine and desipramine plasma levels: how are they related to antidepressant response?
    Stern SL; Cooper TB; Nelson LD; Johnson MH; Suckow RF
    Int Clin Psychopharmacol; 1996 Dec; 11(4):219-27. PubMed ID: 9031987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent treatment of nonresistant major depression with desipramine and lithium: a double-blind, placebo-controlled study.
    Bloch M; Schwartzman Y; Bonne O; Lerer B
    J Clin Psychopharmacol; 1997 Feb; 17(1):44-8. PubMed ID: 9004056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.
    Spina E; Gitto C; Avenoso A; Campo GM; Caputi AP; Perucca E
    Eur J Clin Pharmacol; 1997; 51(5):395-8. PubMed ID: 9049581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management.
    Gonzalez G; Feingold A; Oliveto A; Gonsai K; Kosten TR
    Am J Drug Alcohol Abuse; 2003 Aug; 29(3):497-514. PubMed ID: 14510037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of desmethylimipramine on natural killer cell activity.
    Miller AH; Asnis GM; van Praag HM; Norin AJ
    Psychiatry Res; 1986 Sep; 19(1):9-15. PubMed ID: 3786601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma MHPG in depression: effects of acute and chronic desipramine treatment.
    Charney DS; Heninger GR; Sternberg DE; Roth RH
    Psychiatry Res; 1981 Oct; 5(2):217-29. PubMed ID: 6945615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alprazolam: an antidepressant? Alprazolam, desipramine, and an alprazolam-desipramine combination in the treatment of adult depressed outpatients.
    Fawcett J; Edwards JH; Kravitz HM; Jeffriess H
    J Clin Psychopharmacol; 1987 Oct; 7(5):295-310. PubMed ID: 3316312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of 2-hydroxydesipramine plasma concentrations.
    Nelson JC; Bock JL; Jatlow PI
    Clin Pharmacol Ther; 1983 Feb; 33(2):183-9. PubMed ID: 6822031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidepressant activity of 2-hydroxydesipramine.
    Nelson JC; Mazure C; Jatlow PI
    Clin Pharmacol Ther; 1988 Sep; 44(3):283-8. PubMed ID: 3416551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of desipramine in endogenomorphically depressed patients.
    Stewart JW; Quitkin F; Fyer A; Rifkin A; McGrath P; Liebowitz M; Rosnick L; Klein DF
    J Affect Disord; 1980 Sep; 2(3):165-76. PubMed ID: 6210722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depression and reduced natural killer cytotoxicity: a longitudinal study of depressed patients and control subjects.
    Irwin M; Lacher U; Caldwell C
    Psychol Med; 1992 Nov; 22(4):1045-50. PubMed ID: 1488477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action.
    Delgado PL; Miller HL; Salomon RM; Licinio J; Krystal JH; Moreno FA; Heninger GR; Charney DS
    Biol Psychiatry; 1999 Jul; 46(2):212-20. PubMed ID: 10418696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to desipramine treatment in adolescent major depression.
    Boulos C; Kutcher S; Marton P; Simeon J; Ferguson B; Roberts N
    Psychopharmacol Bull; 1991; 27(1):59-65. PubMed ID: 1862207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpersonal improvement in chronically depressed patients treated with desipramine.
    Markowitz JC; Friedman RA; Miller N; Spielman LA; Moran ME; Kocsis JH
    J Affect Disord; 1996 Nov; 41(1):59-62. PubMed ID: 8938206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desipramine treatment of alcoholism.
    Mason BJ; Kocsis JH
    Psychopharmacol Bull; 1991; 27(2):155-61. PubMed ID: 1924663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between tricyclic antidepressant plasma levels and clinical response in patients treated with desipramine or doxepin.
    Brunswick DJ; Amsterdam JD; Potter L; Caroff S; Rickels K
    Acta Psychiatr Scand; 1983 Jun; 67(6):371-7. PubMed ID: 6880821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.